ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0376

An Internet-Delivered, Arthritis-Tailored Cognitive Behavioral Therapy for Insomnia Program for People with Co-Morbid Sleep Disturbance: Comparing Baseline Characteristics of Cannabis Users and Non-Users

Nicole Andersen1, Diane Lacaille2, Josee Savard3, Elham Rahme1, Paul Fortin4 and Deborah Da Costa5, 1McGill University, Montreal, QC, Canada, 2Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 3Université Laval, Quebec, Canada, 4Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 5McGill University, Pointe-Claire, QC, Canada

Meeting: ACR Convergence 2025

Keywords: Arthritis, Infectious, Outcome measures, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The use of cannabis among individuals with rheumatologic conditions has gained increasing attention due to potential effects on pain, mood, and overall quality of life. However, data on its frequency of use, motivations, and patient-reported outcomes remain limited. We compared cannabis users and non-users by sociodemographic and arthritis characteristics and HRQL, and explored motivations for use, and assessed differences in HRQL among people with rheumatic diseases.

Methods: Data are from the baseline visit of a pilot study of people with inflammatory rheumatic diseases who volunteered for an internet-based intervention to improve sleep. Participants self-reported cannabis use, reasons for consumption, and completed the PROMIS-29 questionnaire (physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social participation). Characteristics were compared between cannabis users and non-users using t-test and chi-square. Associations between cannabis use, demographics, and clinical characteristics were examined using multivariable regression.

Results: Our sample had a mean (SD) age of 54 (14) and 98% were female. Most had RA or PSA, with a mean disease duration of 10 (11) years; many also had OA (30%; Table 1). One third reported using cannabis use in the past year, and 24% in the past 3 months (of which 38% used weekly and 31% daily/almost daily). All participations indicated they were using for medicinal reasons only (100%), with primary motivations being to improve pain (19%), sleep (17%), fatigue (< 5%) or anxiety (< 5%). Nearly half (46%) reported a little improvement in arthritis symptoms with use, with 15% reporting a lot of improvement, 31% no change, and 8% were unsure. Compared to Non-Users, Users reported significantly higher anxiety (p=.046) and depression (p=.014). However, logistic regression results suggested cannabis use was not associated with differences in PROMIS-29 outcomes.

Conclusion: One in three participants in an online intervention to improve sleep reported using cannabis in the past year to improve their arthritis symptoms, with nearly a quarter using cannabis regularly to improve pain, sleep, fatigue and anxiety. User did not report different PROMIS-29 outcomes, although 61% reported a little to a lot of symptom improvement. Understanding the motivations and health impact of cannabis use can help guide patient counseling and future research on alternative management strategies for pain and mood disorders.

Supporting image 1

Supporting image 2


Disclosures: N. Andersen: None; D. Lacaille: None; J. Savard: None; E. Rahme: None; P. Fortin: AbbVie/Abbott, 1, AstraZeneca, 1, Moderna, 1, Roche, 1; D. Da Costa: None.

To cite this abstract in AMA style:

Andersen N, Lacaille D, Savard J, Rahme E, Fortin P, Da Costa D. An Internet-Delivered, Arthritis-Tailored Cognitive Behavioral Therapy for Insomnia Program for People with Co-Morbid Sleep Disturbance: Comparing Baseline Characteristics of Cannabis Users and Non-Users [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/an-internet-delivered-arthritis-tailored-cognitive-behavioral-therapy-for-insomnia-program-for-people-with-co-morbid-sleep-disturbance-comparing-baseline-characteristics-of-cannabis-users-and-non-us/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-internet-delivered-arthritis-tailored-cognitive-behavioral-therapy-for-insomnia-program-for-people-with-co-morbid-sleep-disturbance-comparing-baseline-characteristics-of-cannabis-users-and-non-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology